Jiangsu Weikeli medicine class 1.1 new drug Viagra approved clinical

The class 1.1 new drug Viagra (tablet) of Jiangsu Weikeli Pharmaceutical Technology Co., Ltd was declared in May 2014, and was approved for clinical application on March 10, 2015 The review time is 10 months, and the current processing status is "in approval", involving the acceptance numbers of cxhl1400354, cxhl1400357 and cxhl1400358 What kind of medicine is vicargyle? The target of wicagrel is P2Y12 ADP receptor inhibitor, which can inhibit platelet aggregation The research and development of wicagrel is based on the best-selling drug clopidogrel Some pre clinical research results were published in Journal of medical chemistry in 2012 The results show that CYP2C19 patients with weak metabolism have no drug resistance to vecargrel, and they are safer and faster to take effect, which is expected to become a more effective and safer antiplatelet drug Beloved vicargyle: insight, a university cooperation and group investment, has introduced that vicargyle is a new antithrombotic drug of category 1.1 jointly developed by Jiangsu weicel and China Pharmaceutical University through industry university research cooperation The research and development of the drug took more than three years and invested 10 million yuan In addition to university cooperation, Jiangsu Weikeli also joined hands with Yatai group (SH: 600881), and reached a cooperation agreement with its wholly-owned subsidiary Jilin Yatai Group Pharmaceutical Investment Co., Ltd Yatai group held 60% of Jiangsu Weikeli through acquisition and capital increase Will Vicky gray be the next blockbuster? Wicagrel, which is favored by many parties, is regarded as the next blockbuster because of its better efficacy than clopidogrel in preclinical research? At present, the listed antiplatelet drugs of thiophene pyridine include: clopidogrel, the best-selling drug of Sanofi, prasugrel of Lilly and tegrilol of AstraZeneca Among them, clopidogrel's first and second imitations have occupied the Chinese market, and nearly 100 enterprises have applied for it, while more than 10 enterprises have applied for prasugrel and tegrilol 3.1 drugs In addition, the improvement of wicagrel is mainly to overcome the risk of clopidogrel in 30% of white patients with weak CYP2C19 metabolism, and whether the rest of the patients will pay for it is also a question About Jiangsu weicel Pharmaceutical Technology Co., Ltd Jiangsu weicel Pharmaceutical Technology Co., Ltd ( Com) was founded in September 2010 with a registered capital of 13.5 million yuan It is a high-tech biomedical enterprise established and managed by the entrepreneurial team of overseas students The company is located in No 15, Wanshou Road, Pukou Economic and Technological Development Zone, Nanjing, with a research and development center of nearly 2500 square meters The center has a well-equipped synthesis laboratory, preparation and drug analysis laboratory, and adopts international advanced management and operation mode for management In addition, the company has also established industrial partnership with a number of manufacturers, which have laid a good foundation for the industrialization and marketization of the project.